Sildenafil can increase the response to inhaled nitric oxide.
Bigatello
L M
LM
Departments of Anesthesia and Critical Care, Respiratory Care Services, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. lbigatello@partners.org
Hess
D
D
Dennehy
K C
KC
Medoff
B D
BD
Hurford
W E
WE
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000280:Administration, Inhalation; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004357:Drug Synergism; D005260:Female; D006344:Heart Septal Defects, Atrial / Q000150:complications; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications; D000860:Hypoxia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008875:Middle Aged; D009569:Nitric Oxide / Q000008:administration & dosage / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use*; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human